title: Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy.
abstract: Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks. All the patients progressed or recurred after chemotherapy including cisplatin. The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively. Nausea and vomiting were almost universal but mild in intensity. One renal failure occurred 6 weeks after the first cycle while the tumor was progressing. No antitumor activity was observed in this heavily pretreated population of patients.
authors.affiliation: Centre Léon Bérard, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Clavel
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
authors.forename: S
authors.initials: S
authors.lastname: Gundersen
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.forename: P
authors.initials: P
authors.lastname: Siegenthaler
authors.forename: J
authors.initials: J
authors.lastname: Renard
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
authors.forename: H M
authors.initials: HM
authors.lastname: Pinedo
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D013724:Teratoma / Q000097:blood / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin